Nektar Therapeutics

Nektar Therapeutics Q2 2008 Earnings Call Transcript

Seeking Alpha (Free subscription) | 09/08/2008

Nektar Therapeutics (NKTR) Q2 2008 Earnings Call Complete Story »

Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer

Red Orbit (Free subscription) | 07/08/2008

SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics today announced the appointment of Randall Moreadith, M.D., Ph.D., to the position of Senior Vice President of Drug Development and Chief Development Officer effective August 11, 2008. Dr.

• Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer - PR News Wire

Nektar Q2 loss widens 21%

bizjournals (Free subscription) | 06/08/2008

Nektar Therapeutics on Wednesday reported a second quarter loss of $33.4 million, or 36 cents a share, widened from a loss of $27.5 million, or 30 cents a share in the same period last year. (NKTR)

Nektar Therapeutics Announces Second Quarter 2008 Results

PR News Wire (Free subscription) | 06/08/2008

SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: ) today announced the company's financial results for the second quarter and six-months ended June 30, 2008. Cash, cash equivalents, and short-term investments were $373.9 million at June 30, 2008 compared to $412.6 million at March 31, 2008. Revenue for the three month period ended June 30, 2008 was $20.4 million...

New Positive Data Announced For NKTR-102 (PEG-irinotecan), Highlights Promise Of Nektar's Innovative Small Molecule PEG-Oncolytics

Medical News Today (Free subscription) | 03/06/2008

Nektar Therapeutics (Nasdaq: NKTR) announced new positive data from a Phase 1 clinical study for NKTR-102 (PEG-irinotecan) in advanced cancer patients whose tumors had progressed on other therapies. Significant anti-tumor activity was observed in all dose schedules of the study for NKTR-102 with partial responses observed in seven out of 44 total patients (16 percent) in the trial.

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

Medical News Today (Free subscription) | 03/06/2008

Nektar Therapeutics (Nasdaq: NKTR) announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer patients with K-Ras mutated gene status in its Phase 2 study in advanced colorectal cancer.

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-Irinotecan)

Red Orbit (Free subscription) | 30/05/2008

SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr.

• Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan) - The Earth Times Online Newspaper
• Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan) - PR News Wire

Former Merck exec reunites with ex-boss at Nektar

The San Francisco Business Times (Free subscription) | 22/05/2008

Merck & Co. executive Bharatt Chowrira is being reunited with former boss Howard Robin at Nektar Therapeutics Inc. (NKTR) (MRK) (PFE)

Nektar names Bharatt Chowrira COO

bizjournals (Free subscription) | 22/05/2008

Nektar Therapeutics Inc. on Thursday named Bharatt Chowrira chief operating officer and head of the company's PEGylation Business Unit. (NKTR)

Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit

PR News Wire (Free subscription) | 22/05/2008

SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: ) announced today that Bharatt Chowrira, Ph.D., J.D. has joined the Company as Chief Operating Officer and Head of the PEGylation Business Unit. His responsibilities include overseeing and managing all aspects of the PEGylation Business Unit, including research and manufacturing, as well as operations across the Company....

Bayer and Nektar Report Positive Results From Phase II Pneumonia Trial

Red Orbit (Free subscription) | 20/05/2008

Bayer HealthCare and Nektar Therapeutics have reported positive preliminary Phase II data on their drug-device combination Amikacin Inhale.

Nektar Therapeutics Q1 2008 Earnings Call Transcript

Seeking Alpha (Free subscription) | 19/05/2008

Nektar Therapeutics (NKTR) Q1 2008 Earnings Call Complete Story »

Significant Anti-Tumor Activity Of NKTR-102 In Patients With Refractory Solid Tumors; Interim Data Published In ASCO 2008 Proceedings

Medical News Today (Free subscription) | 17/05/2008

Nektar Therapeutics (Nasdaq: NKTR) announced initial results from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors.

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim ...

Life Science World (Free subscription) | 16/05/2008

[NEWS] Nektar’s Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity SAN CARLOS, Calif., May 16 /PRNewswire-FirstCall/ — Nektar Therapeutics (Nasdaq: NKTR) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors. The study also demonstrates...

• Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings - PR News Wire

Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted By Data Presented at 45th ERA-EDTA Congress

Red Orbit (Free subscription) | 12/05/2008

SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics highlighted today that its proprietary PEGylation technology is used in the novel therapeutic, Hematide(TM), a synthetic, peptide-based erythropoiesis-stimulating agent that is under development by Takeda Global Research & Development Center, Inc.